Use of PPIs tied to drug-induced lupus erythematosus:JAMA
France: Proton pump inhibitors (PPIs) are linked with pharmacovigilance signals for the occurrence of drug-induced lupus erythematosus (DILE), states a research letter published in JAMA Dermatology.
Previous studies have suggested the role of proton pump inhibitors in the occurrence of DILE for drug-induced cutaneous lupus erythematosus (DI-CLE) and systemic lupus erythematosus (DI-SLE) but are not adequately characterized. Therefore, Pauline Bataille and the research team from France aimed to investigate the pharmacovigilance signal of PPI-associated DILE. For this purpose, they used different indicator tools for disproportionate reporting. They also sought to better characterize the spectrum of PPI-associated DILE by zeroing in on DILE type and therapeutic management.
In the analysis, the researchers included DILE cases reported by a physician after Jan. 1, 2002. They described the "immunological, clinical and therapeutic" management of suspected PPI-associated DILE.
The study demonstrated the following findings:
- A total of 21,104,559 cases reported between January 1995 and December 2019 were included in the VigiBase database, among which 625 were identified as DILE associated with a PPI. Among 307 of the cases, a PPI was the only drug suspected. Omeprazole was the PPI most often involved, at 30.4% of cases.
- The analysis of the French database yielded 60 cases of proton pump inhibitor-associated DILE, of which 49 were included for analysis following review.
- Esomeprazole (Nexium, GlaxoSmithKline) was the most common inhibitor in this group and was involved in 46.9% of cases.
- Treatment was ended in 35 of 41 patients. Of these 35 patients, 51.4% achieved disease remission without specific treatment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.